Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Roivant
Biotech
Pfizer closes R&D unit that spawned $7.1B anti-TL1A med
The now-shuttered R&D subunit helped spawn new medicines, including Roivant's $7.1 billion anti-TL1A med.
Max Bayer
Apr 17, 2024 7:00am
Roivant's inflammatory med is back on track with ph. 2 NIU data
Apr 2, 2024 10:37am
JPM24: Roivant CEO has ‘pangs of regret’ for letting Telavant go
Jan 12, 2024 10:30am
Immunovant posts midphase FcRn data in Graves’, plots next steps
Dec 21, 2023 7:00am
Roche pays $7B to challenge Merck for bowel disease market
Oct 23, 2023 6:00am
Lokavant snares $8M investment to expand its presence in Asia
Oct 5, 2023 9:20am